Pharmos tests safety of potential pain treatment
8th Sep 2005, 10:45 GMT
Israeli firm Pharmos has initiated a phase I trial of its potential pain treatment Cannabinor, a CB2-selective synthetic cannabinoid, to assess the safety, tolerability and pharmacokinetics of the compound.
Latest news from Pharmaceutical Business Review Online:
- Celesio revenues, profits up
- Amgen arthritis drug shows sustained safety and efficacy
- Study supports cardiovascular safety of naproxen
- Cangene chickenpox drug granted orphan status
- Reata brain cancer therapy shows strong activity
- Novartis diabetes drug faces three month delay
- Favrille drug fails secondary goal
- Neurogen commences human testing of obesity drug
- Aeterna prostate cancer drug shows promise
- Isis says new drug effective against cholesterol